3 - Picard Medical, Inc. (0002030617) (Issuer)

PRE 14A - Picard Medical, Inc. (0002030617) (Filer)

424B3 - Picard Medical, Inc. (0002030617) (Filer)

EFFECT - Picard Medical, Inc. (0002030617) (Filer)

S-1/A - Picard Medical, Inc. (0002030617) (Filer)

S-8 - Picard Medical, Inc. (0002030617) (Filer)

8-K - Picard Medical, Inc. (0002030617) (Filer)

8-K - Picard Medical, Inc. (0002030617) (Filer)

8-K - Picard Medical, Inc. (0002030617) (Filer)

8-K - Picard Medical, Inc. (0002030617) (Filer)

8-K - Picard Medical, Inc. (0002030617) (Filer)

TUCSON, Ariz., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Dr. Andre Simon, Vice President of Clinical Affairs will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming 19th EUMS (European Mechanical Circulatory Support Summit) & 11th International Course on Mechanical Circulatory Support (MCS) and New Technologies in Advanced Heart Failure (HF) congress, being held February 15th - 18th, 2026 in Barcelona, Spain. Details of the pres

TUCSON, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Matt Schuster, Chief Operating Officer, will present an update on the Company's fully implantable total artificial heart technology as part of the DeviceTalks Tuesdays webcast series hosted by DeviceTalks. During the session, Mr. Schuster will review preclinical experience with SynCardia's next-generation, fully implantable total artificial heart platform, Emperor. The presentation will include bench and acute in vivo data

TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced the launch of the Cruxx to MedTech Podcast discussing series exploring the SynCardia Total Artificial Heart (STAH) and the next generation, fully implantable Emperor device through the lens of patients and management. Anchored by a powerful patient survival story, the series highlights the real-world impact of the STAH on patients facing end stage heart failure. The discussion then turns to SynCardia System's / Picard Medical's

TUCSON, Ariz., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that on January 5, 2026 SynCardia entered into a development collaboration agreement (the "Agreement") with Hydrix Services Pty Ltd ("Hydrix"), a wholly owned subsidiary of Hydrix Limited (ASX: HYD), to commence an initial development phase for SynCardia's next-generation, fully implantable Total Artificial Heart (TAH) technology, known as the Emperor. As a fully implantable TAH, Emperor would eliminate the use of an external dr

TUCSON, Ariz., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems, LLC, maker of the world's first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada today announced that today announced its attendance at conferences during the week of the 44th Annual J.P. Morgan Healthcare Conference ("JPM week") including at LifeSci Advisors' Corporate Access Event and Lifeblood and Goodwin's CEO-Only MedTech Forum. Information on both events is below. Lifeblood and Goodwin's MedTech CEO-Only ForumDate: January 12, 2026Format: Invite-only discussion forumLocation: InterCont

TUCSON, Ariz., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems, LLC, maker of the world's first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada today announced that it would begin to incorporate an additional design component of an FDA-cleared accessory, CPC1 "Connector Covers", into its SynCardia Total Artificial Heart (STAH) design that is intended to provide comfort during daily activities while reinforcing system safety and reliability. Specifically, the CPC Connector Covers will offer an extra layer of protection over the metal release buttons that

TUCSON, Ariz., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems, LLC, maker of the world's first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada today announced that Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical and SynCardia Systems, LLC, has been elected to the Board of Directors of the Arizona Bioindustry Association (AZBio), the state affiliate in Arizona of the Biotechnology Industry Organization (BIO), the preeminent national association for biotechnology companies His term serving on the board will extend through December 2028.

TUCSON, Ariz., Dec. 24, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it has entered into a definitive agreement for a private placement financing of up to $50.0 million aggregate principal amount of senior secured notes due 2028 together with warrants to purchase common stock of the Company. WestPark Capital Inc. served as Sole Placement Agent. The Company expects to issue an initial $15.0 million principal amount of notes at closing with the option to fund up to an additional $35.0 million

NEW YORK, Dec. 18, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on December 18th Equities are mixed Thursday morning as investors digest fresh economic reports. November CPI marked the first inflation reading since the U.S. government shutdown, with economists expecting a 3.1% year-over-year increase. Weekly jobless claims also dropped, following news that unemployment rose to 4.6% in November.Inspired by Gap's "Better in Denim" campaign, the NYSE la

TUCSON, Ariz., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada, today announced that it will ring the Opening Bell at the New York Stock Exchange on December 18, 2025, marking the Company's transition to the public markets and its continued commitment to advancing total artificial heart therapy for patients with end-stage heart failure. "We are proud to mark Picard Medical's transition to a newly public company," said Patrick NJ Schnegelsberg Chief Executive Officer of Picard